Twist Bioscience Corp
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of December 31, 2025 | 61,274 | $— | $1,806,751 | $(571) | $(1,350,085) | $456,095 | |||
| Issuance of common stock for investment in equity securities | 201 | $— | $10,000 | $— | $— | $10,000 | |||
| Issuance of common stock in connection with asset acquisition | 201 | — | 10,000 | — | — | 10,000 | |||
| Vesting of restricted stock units | 296 | — | — | — | — | — | |||
| Exercise of stock options | 78 | — | 1,789 | — | — | 1,789 | |||
| Issuance of shares under the employee stock purchase plan | 104 | 1 | 2,357 | — | — | 2,358 | |||
| Repurchases of common stock for income tax withholding | — | — | (7) | — | — | (7) | |||
| Stock-based compensation | — | — | 18,948 | — | — | 18,948 | |||
| Other comprehensive loss | — | — | — | (68) | — | (68) | |||
| Net loss | — | — | — | — | (44,021) | (44,021) | |||
| Balances as of March 31, 2026 | 62,154 | $1 | $1,849,838 | $(639) | $(1,394,106) | $455,094 | |||
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of December 31, 2024 | 59,582 | $— | $1,730,092 | $(649) | $(1,273,502) | $455,941 | |||
| Restricted common stock canceled | (137) | $— | $— | $— | $— | $— | |||
| Vesting of restricted stock units | 275 | — | — | — | — | — | |||
| Exercise of stock options | 72 | — | 771 | — | — | 771 | |||
| Issuance of shares under the employee stock purchase plan | 65 | — | 2,429 | — | — | 2,429 | |||
| Repurchases of common stock for income tax withholding | — | — | (4) | — | — | (4) | |||
| Stock-based compensation | — | — | 20,312 | — | — | 20,312 | |||
| Other comprehensive loss | — | — | — | (13) | — | (13) | |||
| Net loss | — | — | — | — | (39,328) | (39,328) | |||
| Balances as of March 31, 2025 | 59,857 | $— | $1,753,600 | $(662) | $(1,312,830) | $440,108 | |||
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of September 30, 2025 | 60,632 | $— | $1,793,163 | $(627) | $(1,319,578) | $472,958 | |||
| Issuance of common stock for investment in equity securities | 201 | $— | $10,000 | $— | $— | $10,000 | |||
| Issuance of common stock in connection with asset acquisition | 201 | — | 10,000 | — | — | 10,000 | |||
| Vesting of restricted stock units | 923 | — | — | — | — | — | |||
| Exercise of stock options | 93 | — | 2,089 | — | — | 2,089 | |||
| Issuance of shares under the employee stock purchase plan | 104 | 1 | 2,357 | — | — | 2,358 | |||
| Repurchases of common stock for income tax withholding | — | — | (9) | — | — | (9) | |||
| Stock-based compensation | — | — | 32,238 | — | — | 32,238 | |||
| Other comprehensive loss | — | — | — | (12) | — | (12) | |||
| Net loss | — | — | — | — | (74,528) | (74,528) | |||
| Balances as of March 31, 2026 | 62,154 | $1 | $1,849,838 | $(639) | $(1,394,106) | $455,094 | |||
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of September 30, 2024 | 58,877 | $— | $1,715,119 | $(522) | $(1,241,908) | $472,689 | |||
| Restricted common stock canceled | (137) | $— | $— | $— | $— | $— | |||
| Vesting of restricted stock units | 811 | — | — | — | — | — | |||
| Exercise of stock options | 241 | — | 3,722 | — | — | 3,722 | |||
| Issuance of shares under the employee stock purchase plan | 65 | — | 2,429 | — | — | 2,429 | |||
| Repurchases of common stock for income tax withholding | — | — | (11) | — | — | (11) | |||
| Stock-based compensation | — | — | 32,341 | — | — | 32,341 | |||
| Other comprehensive loss | — | — | — | (140) | — | (140) | |||
| Net loss | — | — | — | — | (70,922) | (70,922) | |||
| Balances as of March 31, 2025 | 59,857 | $— | $1,753,600 | $(662) | $(1,312,830) | $440,108 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.